Chelation therapy, involving IV infusions of a metal-binding agent, did not show clinical benefit in post-MI patients with diabetes, according to the TACT2 trial. The therapy reduced lead levels in the blood but did not improve cardiovascular outcomes. The trial involved 1,000 patients with diabetes and a prior heart attack who received 40 weekly infusions of edetate disodium or a placebo. No significant differences were found in all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina between the two groups. The decrease in lead levels over time may have affected the therapy’s efficacy. Further research into alternative treatments is recommended.
Source link
Chelation therapy fails to improve cardiovascular outcomes after heart attack: TACT2
